Differential Expression of Functional Protease-Activated Receptor-2 (PAR-2) in Human Vascular Smooth Muscle Cells

From the Department of Medicine and the Center for Experimental Therapeutics of the University of Pennsylvania, Philadelphia (P.N.R., A.K., M.A., J.A.H., L.F.B., E.S.B.); and the Istituto di Ricerche Farmacologiche Mario Negri, Santa Maria Imbaro, Italy (M.M.).

Correspondence to Dr Lawrence F. Brass, University of Pennsylvania, CRB 678, 415 Curie Blvd, Philadelphia, PA 19104. E-mail brass{at}mail.med.upenn.edu

Abstract—The protease-activated family of G protein–coupled receptors includes PAR-1 and PAR-3, which are activated by thrombin, and PAR-2, which is activated by trypsin and tryptase. PAR-2 has recently been shown to be expressed in human endothelial cells. In the present studies, we have examined the expression of PAR-2 in other cells, particularly vascular smooth muscle, and tested whether the receptors are functional. The results show that PAR-2 is present in human aorta and coronary artery smooth muscle cells, as well as in arteries traversing the walls of the small intestine. It was also detected in human keratinocytes, sweat glands, intestinal smooth muscle, and intestinal epithelium, but not at all in myocardial smooth muscle and only inconsistently in intestinal veins and venules. Activation of aortic smooth muscle cells in culture with PAR-2 peptide agonists caused a transient increase in the cytosolic Ca²⁺ concentration. In contrast, PAR-2 mRNA could not be detected in saphenous vein smooth muscle cells, and the same cells placed in culture showed little, if any, response to the PAR-2 agonist peptides. These observations show that PAR-2 is widely distributed in human vascular smooth muscle, particularly in arteries. However, this is not a universal finding and at least some venous smooth muscle cells, including those in saphenous veins, apparently do not express the receptor in detectable amounts.

Key Words: vascular smooth muscle • protease-activated receptor • PAR-2 • thrombin • trypsin

This article has been cited by other articles:

				E. B. Kelso, J. C. Lockhart, T. Hembrough, L. Dunning, R. Plevin, M. D. Hollenberg, C. P. Sommerhoff, J. S. McLean, and W. R. Ferrell Therapeutic Promise of Proteinase-Activated Receptor-2 Antagonism in Joint Inflammation J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1017 - 1024. [Abstract] [Full Text] [PDF]

				F. Roviezzo, M. Bucci, V. Brancaleone, A. Di Lorenzo, P. Geppetti, S. Farneti, L. Parente, G. Lungarella, S. Fiorucci, and G. Cirino Proteinase-Activated Receptor-2 Mediates Arterial Vasodilation in Diabetes Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2349 - 2354. [Abstract] [Full Text] [PDF]

				C Napoli, F de Nigris, J L Wallace, M D Hollenberg, G Tajana, G De Rosa, V Sica, and G Cirino Evidence that protease activated receptor 2 expression is enhanced in human coronary atherosclerotic lesions J. Clin. Pathol., May 1, 2004; 57(5): 513 - 516. [Abstract] [Full Text] [PDF]

				S. He, A. Aslam, M. D. A. Gaca, Y. He, M. G. Buckley, M. D. Hollenberg, and A. F. Walls Inhibitors of Tryptase as Mast Cell-Stabilizing Agents in the Human Airways: Effects of Tryptase and Other Agonists of Proteinase-Activated Receptor 2 on Histamine Release J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 119 - 126. [Abstract] [Full Text]

				C. Cicala, S. Morello, V. Vellecco, B. Severino, L. Sorrentino, and G. Cirino Basal nitric oxide modulates vascular effects of a peptide activating protease-activated receptor 2 Cardiovasc Res, November 1, 2003; 60(2): 431 - 437. [Abstract] [Full Text] [PDF]

				P. J. O'Brien, H. Koi, S. Parry, L. F. Brass, J. F. Strauss III, L.-P. Wang, J. E. Tomaszewski, and L. K. Christenson Thrombin Receptors and Protease-Activated Receptor-2 in Human Placentation: Receptor Activation Mediates Extravillous Trophoblast Invasion in Vitro Am. J. Pathol., October 1, 2003; 163(4): 1245 - 1254. [Abstract] [Full Text] [PDF]

				G. Grandaliano, P. Pontrelli, G. Cerullo, R. Monno, E. Ranieri, M. Ursi, A. Loverre, L. Gesualdo, and F. P. Schena Protease-Activated Receptor-2 Expression in IgA Nephropathy: A Potential Role in the Pathogenesis of Interstitial Fibrosis J. Am. Soc. Nephrol., August 1, 2003; 14(8): 2072 - 2083. [Abstract] [Full Text] [PDF]

				E. Camerer, H. Kataoka, M. Kahn, K. Lease, and S. R. Coughlin Genetic Evidence That Protease-activated Receptors Mediate Factor Xa Signaling in Endothelial Cells J. Biol. Chem., May 3, 2002; 277(18): 16081 - 16087. [Abstract] [Full Text] [PDF]

				P. G. McLean, D. Aston, D. Sarkar, and A. Ahluwalia Protease-Activated Receptor-2 Activation Causes EDHF-Like Coronary Vasodilation: Selective Preservation in Ischemia/Reperfusion Injury: Involvement of Lipoxygenase Products, VR1 Receptors, and C-Fibers Circ. Res., March 8, 2002; 90(4): 465 - 472. [Abstract] [Full Text] [PDF]

				C. Patterson, G. A. Stouffer, N. Madamanchi, and M. S. Runge New Tricks for Old Dogs : Nonthrombotic Effects of Thrombin in Vessel Wall Biology Circ. Res., May 25, 2001; 88(10): 987 - 997. [Abstract] [Full Text] [PDF]

				M. Riewald, V. V. Kravchenko, R. J. Petrovan, P. J. O'Brien, L. F. Brass, R. J. Ulevitch, and W. Ruf Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1 Blood, May 15, 2001; 97(10): 3109 - 3116. [Abstract] [Full Text] [PDF]

				C. Napoli, C. Cicala, J. L. Wallace, F. de Nigris, V. Santagada, G. Caliendo, F. Franconi, L. J. Ignarro, and G. Cirino From the Cover: Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart PNAS, March 28, 2000; 97(7): 3678 - 3683. [Abstract] [Full Text] [PDF]

				C. Napoli, F. De Nigris, C. Cicala, J. L. Wallace, G. Caliendo, M. Condorelli, V. Santagada, and G. Cirino Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H2004 - H2010. [Abstract] [Full Text] [PDF]

				G. Trottier, M. Hollenberg, X. Wang, Y. Gui, K. Loutzenhiser, and R. Loutzenhiser PAR-2 elicits afferent arteriolar vasodilation by NO-dependent and NO-independent actions Am J Physiol Renal Physiol, May 1, 2002; 282(5): F891 - F897. [Abstract] [Full Text] [PDF]

				P. G. McLean, D. Aston, D. Sarkar, and A. Ahluwalia Protease-Activated Receptor-2 Activation Causes EDHF-Like Coronary Vasodilation: Selective Preservation in Ischemia/Reperfusion Injury: Involvement of Lipoxygenase Products, VR1 Receptors, and C-Fibers Circ. Res., March 8, 2002; 90(4): 465 - 472. [Abstract] [Full Text] [PDF]

				J. R. Hamilton, A. G. Frauman, and T. M. Cocks Increased Expression of Protease-Activated Receptor-2 (PAR2) and PAR4 in Human Coronary Artery by Inflammatory Stimuli Unveils Endothelium-Dependent Relaxations to PAR2 and PAR4 Agonists Circ. Res., July 6, 2001; 89(1): 92 - 98. [Abstract] [Full Text] [PDF]